1697-P: Further Real-World Outcomes Using Medication and Intensive Lifestyle Intervention to Treat Obesity and Improve Diabetes at Scale

Introduction: More than 2/3 adults in the US have overweight or obesity. Increasing obesity rates profoundly impact diabetes and cardiometabolic disease. We established a digital metabolic health company to provide medically-supervised obesity treatment at scale. Methods: The program used the combination of GLP-1 medication, medical supervision, and a proprietary lifestyle intervention. Patients who reached at least 12 months (mo) in the core program and a smaller subset who reached 24 mo were analyzed for weight change, metabolic labs (baseline and 12mo) and patient-completed questionnaires (baseline, 6, and 12mo) using data where available in this real-world setting. Results: The cohort who reached at least 12mo included 6,167 patients. For members with HbA1c at both baseline and 12mo (n=2,568), there were 3.4% and 23.7% who met baseline A1c criteria for diabetes and prediabetes. Average weight loss at 12 and 24 months was 16.39% (n=5,341) and 16.02% (n=169). Average weight loss for patients with diabetes or prediabetes at 12, 15 and 18 mo was 15.6% (n=1,375), 16.6% (n=782), and 16.7% (n=385). Patients with diabetes and prediabetes saw average improvements for HbA1c of -1.5 and -0.47 percentage points, respectively. 78.2% of patients with HbA1c levels >5.7% at baseline were